Company news
Arcturus Therapeutics Holdings Inc. news in 2024
Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2024, newest first.
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 15, 2024
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
November 17, 2024
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
November 10, 2024
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
November 6, 2024
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
October 30, 2024
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
September 29, 2024
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
September 12, 2024
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
September 2, 2024
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
August 26, 2024
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
August 4, 2024
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
July 31, 2024
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
July 17, 2024
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
June 30, 2024
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
June 19, 2024
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
June 6, 2024
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
May 27, 2024
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
May 19, 2024
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 19, 2024
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
May 7, 2024
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
April 24, 2024
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
March 6, 2024
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
February 25, 2024
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
February 21, 2024
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
February 19, 2024
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
February 4, 2024
PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems
January 4, 2024
Calls in 2024
- Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q3 2024 Earnings Call
Nov 7, 2024
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q2 2024 Earnings Call
Aug 5, 2024
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2024 Earnings Call
May 8, 2024
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q4 2023 Earnings Call
Mar 7, 2024
Transcript
Decks in 2024
- Investor Presentation (August 2024)
Investor deck · 26 slides · Aug 13, 2024